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httpObjectives: Contrast-enhanced ultrasonography (CEUS) has been used to assess the vascularisation of carotid
plaques. Our aim was to develop and validate a standardised semi-automated method for CEUS examination of
plaques, and test if the technique could be used to identify vulnerable plaques.
Methods: Study participants were a mixed population of symptomatic and asymptomatic subjects, selected if
they had a plaque with height >2.5 mm and <10% acoustic shadowing. Participants received a bolus of
ultrasound contrast agent and a 90-s cine-loop was captured. A Contrast Quantiﬁcation Program (CQP) was
developed and trained to identify extent of contrast uptake after motion correction and application of a noise
reduction algorithm. The technique was validated by comparing CQP values with visual assessment of contrast
uptake. CQP values were also compared with plaque echogenicity and history of clinical events.
Results: CQP values correlated with a visual, 5-scale classiﬁcation of contrast uptake by two blinded, experienced
sonographers. Repeated contrast injections showed high reproducibility. Participants with a history of ipsilateral
stroke/TIA had signiﬁcantly higher CQP values than asymptomatic participants.
Conclusion: We present a reproducible, semi-automatic method to identify vascularisation of carotid plaques,
which could be used in prospective studies to determine the clinical value of plaque vascularisation.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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DiagnosticsINTRODUCTION
Intense efforts have been devoted to developing imaging
techniques for identiﬁcation of vulnerable atherosclerotic
plaques prone to cause clinical events.1,2 It is generally
considered that a large lipid-rich necrotic core and a dense
inﬁltration of inﬂammatory cells, particularly in the
shoulder regions, predicts vulnerability while a thick ﬁbrotic
cap is associated with a more stable plaque phenotype.2,3
However, most evidence to support this concept is based
on autopsy and cross-sectional histological studies.3
Magnetic resonance imaging (MRI) of human carotid pla-
ques has evolved as a promising technique to identify and
quantify these different plaque phenotypes,2,4 but it is too
expensive to use as a diagnostic tool on a large scale. In
addition, the grey scale of ultrasound can be used to
differentiate lipid-rich carotid plaques with low echoge-
nicity from more ﬁbrous tissue with higher
echogenicity.2,5,6rresponding author. O. Hjelmgren, Department of Molecular and
l Medicine, Clinical Physiology, Sahlgrenska Academy at the Univer-
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://dx.doi.org/10.1016/j.ejvs.2013.03.023Recent evidence suggests additional features that are
central in determining the vulnerability of plaques, namely
intra-plaque vascularisation and intra-plaque haemorrhage
(IPH).1,7 IPH likely results from bleeding from immature
vessels formed after vascular proliferation.7 Increased vas-
cularisation has been observed in histological sections of
symptomatic plaques.8 In addition, a large histological study
of carotid endarterectomy specimens showed that IPH was
the aspect of plaque histology that most readily predicted
future cardiovascular events, superior to lipid content and
degree of inﬂammation.9 Furthermore, IPH detected by MRI
has been shown to predict future ipsilateral stroke.10,11
Contrast-enhanced carotid ultrasonography (CEUS) has
been used to measure plaque vascularisation in vivo in
humans,12e18 and several studies have shown a good to
excellent correlation between visual assessment of
ultrasound-assessed contrast uptake in the plaque and the
vascularisation of corresponding histological sections.12,14,15
However, visual assessment is highly user dependent and
difﬁcult to use as a diagnostic tool and in research. Here we
developed and validated a standardised reproducible and
semi-automated method for CEUS examinations of carotid
plaques. In addition, we investigated how contrast enhance-
ment measured with our semi-automated method correlated
with plaque echogenicity measured using standard ultra-
sound imaging as well as with previous clinical events.
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Study population
The subjects consisted of patients selected from the
Western region Initiative to Gather Information on
Atherosclerosis (WINGA) database, which includes patients
at Sahlgrenska University Hospital undergoing ultrasound
examination for suspected cerebrovascular disease, and
healthy volunteers aged 68e73 years identiﬁed through
ofﬁcial registers and invited to screening for carotid artery
atherosclerosis.
Inclusion criteria were at least one carotid plaque with
minimum height 2.5 mm and an acceptable acoustic
window where <10% of the plaque surface had ultrasound
acoustic shadowing. Exclusion criteria were: age >80 years;
history of myocardial infarction; cardiac surgery or percu-
taneous coronary interventions within the previous
6 months; angina pectoris; right to left heart shunts; severe
arrhythmias; pulmonary hypertension; uncontrolled
systemic hypertension (>180/110 mmHg); heart failure
with symptoms in NYHA class III-IV; advanced chronic
obstructive pulmonary disease; multiple transient ischaemic
attacks (TIA) within the previous 2 weeks; unable to
communicate in written and spoken Swedish.
The study conforms to the Declaration of Helsinki and has
been approved by the ethics committee at Sahlgrenska
Academy, Gothenburg University. All subjects gave written,
informed consent.Baseline characteristics
Subjects were invited to the laboratory and detailed clinical
and life style data were collected using a standardised
questionnaire. Data on anthropometry, blood pressure and
ECG were collected and venous blood samples were drawn
as previously described.19Image acquisition
Subjects were imaged using a Siemens S2000, update
VA16D, ultrasound platform (Siemens, Mountain View,
California, USA) equipped with a 9L4 probe used at 9 MHz
for standard imaging and 4 MHz for cadence imaging. A
longitudinal transducer position was chosen to show an
image-plane perpendicular through the centre of the vessel
and through the maximum height of the plaque. The full
length of the carotid arteries were scanned, and short, B-
mode cine loops of all plaques fulﬁlling the inclusion criteria
were stored digitally.
Cadence contrast pulse sequencing (CPS) technology for
Siemens S2000 was used to image contrast uptake in the
plaques identiﬁed by B-mode imaging. We performed
a separate series of 15 pilot experiments to optimise the
settings for the cadence CPS and the dose of contrast agent
(Sonovue, Bracco Imaging, Milan, Italy). These experiments
also showed that the critical minimum height of the plaque
should be 2.5 mm. The protocol was then ﬁxed and not
altered throughout the examinations presented in this
paper.The standardised image settings included a low
mechanical index (0.06) and a low overall 2D-gain focusing
on the contrast agent and making the tissue less prominent.
In the pilot experiments we found that an MI of 0.06 was
the optimal setting that could be used without losing image
information. The CPS image without contrast in the lumen
should be almost completely black. The contrast agent was
injected as a bolus (1.6 ml) in a peripheral vein and ﬂushed
with 10 ml of saline according to the manufacturer’s
instructions (Bracco Imaging, Milan, Italy). The sonographer
aimed at imaging the plaque at a ﬁxed insonation angle and
a DICOM cine loop was recorded for 150 s starting when the
contrast bolus was injected. Each subject received 2 or 3
bolus injections, each separated by a 30-min washout
period.Analysis of B-mode images
For the images obtained using standard B-mode ultrasound
(Fig. 1A), plaque size was measured and echogenicity was
assessed using the visual Gray-Weale scale and the auto-
mated Grey Scale Median (GSM) and Percentage White
(PW) scale using semi-automated software.20Analysis of CEUS images by Contrast Quantiﬁcation
Program (CQP)
All handling and analyses of CEUS images were integrated
in CQP, our development software platform. The 150-
s contrast loop was stored in DICOM format at 24 or 26
frames per second and each frame was later converted
into bitmap ﬁles. The ﬁrst image frame showing contrast in
the arterial lumen was identiﬁed and set as the starting
frame (Fig. 1B). The series of frames was resampled from
the starting frame extracting one frame per second for
90 s.
CQP was developed to analyse contrast uptake in the
image loop in a series of standardised steps:
(1) The plaque border was manually outlined using
a region of interest (ROI) on a frame in which the
vessel lumen was ﬁlled with contrast (Fig. 1C).
(2) All images in the series were manually motion
corrected using the ﬁxed ROI, which could be moved
and tilted.
(3) In every frame, the mean pixel intensity in a reference
area, placed in the carotid lumen close to the plaque
(Fig. 1B), was calculated. The highest and lowest values
of mean intensity during the series of frames were
used as white and black references, respectively. In all
frames, a linear normalisation was performed where
the black reference pixel intensity value was set to 10
and the white reference pixel intensity value was set to
200.
(4) If the image plane was lost for a short period (for
example, if the subject swallowed) and the image
plane was then restored by the technician, the affected
frames were excluded and given a value interpolated as
the mean of the values from the adjacent frames.
Figure 1. A: B-mode image of plaque with low echogenicity in the near wall of the internal carotid artery/bulb. B: Screenshot from CQP
software when ﬁrst contrast bubble arrives in vessel lumen. Note artefact area marked green. C: Screenshot from the CQP software. Plaque
borders marked orange; intensity reference area marked blue; manually excluded area marked green. D: Processed image from CQP.White
area inside plaque border indicates contrast containing area. 81% of plaque area is contrast containing.
O. Hjelmgren et al. 23(5) A noise reduction and contrast detection algorithm was
developed. A pixel was considered contrast positive if
the intensity exceeded 35 (the noise threshold), for at
least 14% of the time.
(6) To compensate for inexact motion correction, a border
of four pixels (0.25 mm) was subtracted from the
plaque ROI.
(7) The percentage of pixels in the plaque with a contrast
intensity exceeding those set by the time-intensity
algorithmduring the 90-s loopwas calculated and used as
an index of contrast uptake; this was termed “CQP value.”Training and validation of CQP
Training and validation of the CQP followed standard
guidelines for development of pattern recognition soft-
ware.21 The CQP was trained on 10 plaques from 10
subjects showing a range of contrast uptake from zero to
maximum intensity. The CPS DICOM loops were converted
to AVI ﬁles and visually classiﬁed by two experienced
sonographers (UP and CS) blinded for the selection process
and CQP data. The sonographers graded the contrast uptake
inside each plaque on a ﬁve-grade scale and the average
result of the two sonographers was used for the correlation
analysis. The correlation coefﬁcient between CQP values
and visual assessment was used to select the best noise
reduction algorithm.
Correlation coefﬁcients ranged from 0.59 to 0.93
depending on which time-intensity thresholds were used.
The highest correlation was obtained when we deﬁned
pixels as white if their intensity was >35 at least 14% of the
time. The selected algorithm was then validated by testing
the ability of the program to identify the degree of contrast
uptake by comparing the visual assessment with CQP valuesin a consecutive series of 48 plaques from 45 subjects. To
achieve a consecutive series of examinations, seven of the
plaques came from the CQP training data set. Validation
data were analysed both with and without these seven
plaques. Blinded evaluation of visual uptake served as
a reference.
In some plaques, strong hyper-echogenic areas appeared
inside the plaque when imaged using CPS (see Fig. 1B and
C). The areas showed a strong echo signal even when no
contrast was given and ﬂared up when contrast was
present. We consider these areas to be artefacts, which the
CPS cannot ﬁlter. We performed the CQP analysis both with
and without these areas. We excluded these areas both
manually and by using an automatic algorithm that we
developed. The automatic algorithm calculates the mean
intensity in the reference area in every frame (see above);
for every frame, pixels inside the plaque that show intensity
higher than the mean value are considered as artefacts.CQP and plaque vulnerability
The CQP was used to analyze plaques in a consecutive
series of 52 subjects, of which the ﬁrst 45 subjects came
from the validation group. In subjects with more than one
identiﬁed plaque, the plaque with the largest surface area
was chosen. Data on previous clinical events were collected
from patient records and the detailed questionnaire.Reproducibility
To assess reproducibility we examined the ﬁrst 20 subjects
from the total group of 52 subjects in which we were able
to perform two successful contrast examinations of the
same plaque in the same insonation angle separated by
a 30-min washout period. The washout time was set at
24 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 1 July/201330 min because there was no visually detectable contrast
left in any of the subjects after this time.
Statistical methods
The SPSS 20 statistical software package was used.
Continuous data are presented as median and interquartile
range (IQR). Mann-Whitney U test was used for paired
comparisons. Correlations were evaluated using Spearman
correlation coefﬁcients. Reproducibility was evaluated using
limits of agreement and intra class correlation and Bland-
Altman plots. ANOVA or Kruskall-Wallis H test were used
where appropriate. Power calculations were made using
t-test. P < 0.05 (two-sided) was considered to be statisti-
cally signiﬁcant.
RESULTS
Recruitment
Between January 2010 and June 2011, a total of 787
patients gave informed consent to enter the WINGA data-
base. Of these, 514 (65%) had one or more carotid plaques,
237 (30%) had a plaque with a height of at least 2.5 mm and
162 (21%) had a plaque suitable for contrast examination
(<10% acoustic shadowing). Of these 162 patients, 72
patients (9% of the total) met the inclusion and exclusion
criteria and 40 patients gave informed consent to CEUS
examination. Thirty-three of these patients were examined
with CEUS and 30 patients were included in the current
study. These 30 participants had a slightly lower plaque
echogenicity compared with the 42 patients who met the
inclusion and exclusion criteria but were not examined by
CEUS, but this difference was not signiﬁcant, and thereTable 1. Characteristics of subjects according to experimental group.
range.
All subjects
n ¼ 52
Age (years) 68 (63e72)
Sex (Female) 35%
Weight (kg) 79 (65e90)
BMI (kg/m2) 24.8 (22.8e27.6)
Systolic blood pressure (mmHg) 138 (128e146)
Diastolic blood pressure (mmHg) 78 (68e80)
hs-CRP 1.41 (1.01e2.89)
Serum cholesterol (mmol/L) 5.2 (4.4e6.2)
Serum LDL cholesterol (mmol/L) 3.0 (2.1e4.0)
Serum HDL cholesterol (mmol/L) 1.74 (1.4e2.2)
Current smoking 23%
Previous smokers 27%
Never smokers 50%
History of Diabetes 8%
History of Hypertension 64%
History of Myocardial Infarction 8%
History of Stroke or TIA 50%
History of Ipsilateral Stroke or TIA 19%
Statin treatment >3months 35%
Anti platelet treatment >3 months 38%
Warfarin treatment >3 months 6.5%
a ANOVA or Kruskall-Wallis H test or Pearson Chi-square when appropwere no differences in plaque size, age or gender (data not
shown).
In the non-hospital-based recruitment of healthy volun-
teers, a total of 310 healthy volunteers were screened and
22 (7%) fulﬁlled the criteria for inclusion and participated in
the study. In total, 52 subjects were included in the analysis
contributing a total of 55 plaques. Characteristics of the
subjects are shown in Table 1.Adverse events
One subject experienced a short period of itching in the
hands lasting up to one minute after contrast
administration.Validation of CQP
The validation data set consisted of 48 plaques. Five of
these plaques were deemed “not suitable for visual
assessment of contrast uptake” by one or both sonogra-
phers, and were excluded from the analysis. The ﬁnal vali-
dation set thus comprised 43 plaques from 41 subjects.
Characteristics of the validation group are shown in Table 1.
Reproducibility analyses showed moderate inter-observer
agreement between the two visual observers, weighted
kappa ¼ 0.58. The average result of the two visual
observers was then used for analyzes.
The visual assessment of CEUS uptake correlated with
non-corrected CQP values (r ¼ 0.64, r < 0.001) and with
CQP values corrected for visually detected artefacts
(r ¼ 0.68, p < 0.001; Fig. 2) and automatically detected
artefacts (r ¼ 0.65, p < 0.001). When the seven plaques
that were part of the training set were excluded, theContinuous variables are presented as median and inter quartile
Validation group
n ¼ 41
Reproducibility group
n ¼ 20
ap-value
68 (63e72) 67 (62e72) 0.43
33% 55% 0.20
78 (65e90) 72 (60e85) 0.34
25.1 (22.9e27.6) 23.8 (21.5e26.9) 0.48
138 (130e148) 137 (127e147) 0.59
78 (69e81) 71 (60e80) 0.46
1.42 (0.96e3.01) 1.34 (0.9e2.32) 0.93
5.2 (4.3e6.3) 5.1 (4.7e6.2) 0.91
2.8 (2.1e4.0) 2.9 (2.1e4.0) 0.95
1.7 (1.4e2.2) 1.8 (1.4e2.3) 0.81
19% 20% 0.93
28% 20% 0.93
54% 60% 0.93
2% 5% 0.50
70% 75% 0.61
7% 5% 0.92
51% 50% 0.99
16% 20% 0.91
37% 35% 0.97
37% 35% 0.97
9.3% 5% 0.80
riate.
Figure 2. Correlation between CQP values (invalid areas manually
excluded) and visual classiﬁcation in the validation data set (n¼ 43
plaques from 41 subjects).
O. Hjelmgren et al. 25corresponding correlation coefﬁcients were r ¼ 0.51,
r ¼ 0.60 and r ¼ 0.55 (all p < 0.001). We also observed that
CQP values were skewed towards low values suggesting low
contrast uptake in most of the plaques (Fig. 3).
Artefacts were found in almost every plaque using the
automatic algorithm; however, most of them were very
small. Visually detected artefacts were found in 43% of the
plaques. These plaques were signiﬁcantly smaller than
those without artefacts (median area 28 mm2 IQR 23e44 vs
40 mm2 IQR 25e60, p ¼ 0.02). No signiﬁcant difference in
plaque location was seen: 33% of plaques with artefacts
were found in the near wall compared with 39% of plaques
without artefacts. We did not observe any difference in
echogenicity between plaques with and without artefacts
when we used GSM (41 IQR 28e63 vs 36 IQR 28e52,
p ¼ 0.37); however, plaques with artefacts had a slightlyFigure 3. Distribution of CQP values in the validation data set
(n ¼ 43 plaques from 41 subjects).higher echogenicity when assessed using PW (29 IQR 15e
38 vs 17 IQR 9e28, p ¼ 0.04).
Reproducibility of CQP
Characteristics of the 20 subjects included in the repro-
ducibility study are shown in Table 1. Repeated analysis of
a single examination showed a high intra-observer repro-
ducibility with no systematic difference between the ﬁrst
and second CQP analyses (Fig. 4A). Analysis of the ﬁrst and
second examinations separated by a 30-min washout
showed a high inter-observer reproducibility with no
systematic difference between the two examinations
(Fig. 4B). Based on the standard deviation measured in the
inter observer-variability study we made a power calcula-
tion for a hypothetical treatment study with CQP value as
primary outcome. We assumed a 10% decline of CQP value
in the treatment group and no change in the placebo group.
These assumptions give 80% power to detect 10% changes
in contrast uptake if 30 patients are included in each group.
Contrast uptake is associated with echogenicity and
history of clinical symptoms
After developing and validating the CQP, we used this
technique to analyse plaques in our total population of 52
consecutively recruited subjects and compared CQP valuesFigure 4. A: Bland-Altman plot showing differences between
repeated analyses of a single examination. B: Bland-Altman plot
showing differences between ﬁrst and second examinations per-
formed with 30-min wash-out period between examinations
(n ¼ 20).
Figure 5. Correlation between Grey Scale Median and CQP values
in all subjects (n ¼ 52). Figure 6. Box plot showing CQP values for subjects without history
of ipsilateral stroke or TIA (n ¼ 42) and with history of ipsilateral
stroke or TIA (n ¼ 10). Box perimeters indicate 25th and 75th
percentile. Horizontal line inside box indicates median. Antennas
outside box indicate range.
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imaging) and previous clinical events (shown in Table 1).
Most of the plaques in our study had low echogenicity
with 61% of plaques assigned a Gray-Weale score of 1 or 2.
Surprisingly, we observed signiﬁcant positive correlations
between CQP values and plaque echogenicity classiﬁed by
GSM (Fig. 5) and by Gray-Weale and PW (data not shown)
Table 2.
We observed a tendency toward higher CQP values in
subjects with previous history of symptoms regardless of
type of event compared with asymptomatic individuals
(data not shown). This tendency reached statistical signiﬁ-
cance in subjects with a history of ipsilateral stroke/TIA
(Fig. 6). In contrast, there were no differences between
groups in plaque characteristics derived from B-mode
imaging.
It has been shown that contrast uptake in far-wall pla-
ques may be artifactually enhanced by so-called pseudo-
enhancement.22 To address this we analysed far- (n ¼ 31)
and near-wall (n ¼ 21) plaques separately. We observed
signiﬁcantly higher CQP values in far-wall plaques than
near-wall plaques (35 IQR 20e71 vs. 10 IQR 5e37,5,
p ¼ 0.007). However, when near and far-wall plaques were
analyzed separately there was still a signiﬁcantly higher CQPTable 2. Characteristics of plaques according to experimental group.
All subjects
n ¼ 52
Valid
n ¼
Plaque area (mm2) 33.8 (25.2e44.3) 33.5
Plaque height (mm) 3.47 (2.98e4.04) 3.42
Plaque location (near wall) 40% 42%
Percentage White (%) 21 (12e33) 20 (1
Grey Scale Median 40 (29e56) 40 (2
Gray-Weale class I (echolucent) 28% 26%
Gray-Weale class II
(Mostly echolucent)
67% 65%
CQP (%)
Manually invalid area exclusion
29 (9e53) 22 (8
CQP (%)
Automatic invalid area exclusion
30 (8e53) 29 (7
CQP (%)
Without invalid area exclusion
32.5 (9e59) 32 (9
a ANOVA or Kruskall-Wallis H test when appropriate.in the symptomatic plaques in the far-wall (p ¼ 0.048) and
a strong tendency for a higher CQP in symptomatic plaques
in the near wall (p ¼ 0.08) compared to asymptomatic
plaques.DISCUSSION
Here we describe a standardised examination protocol to
objectively measure ultrasound contrast uptake in carotid
plaques. The values obtained using our semi-automated
method correlated with visual assessment of contrast
uptake and were reproducible. Furthermore, we showed
that contrast enhancement measured with our semi-
automated method correlated with plaque echogenicity
(measured using standard ultrasound imaging) and with
previous cerebrovascular symptoms.
Earlier reports that measure contrast uptake used a semi-
quantitative visual approach.12,13,15,16,18 Although the semi-
quantitative data correlate well with histological estimates
of vascularisation,12,14,15 the interpretation is highly user
dependent and not suitable for multi-centre trials or serialation group
43
Reproducibility group, n ¼ 20 ap-value
(24.4e42.7) 33.1 (23.2e42.1) 0.89
(2.96e3.77) 3.37 (2.98e3.72) 0.81
35% 0.87
2e32) 29 (17e40) 0.43
9e55) 43 (33e41) 0.41
(11) 21% 0.99
(28) 68% 0.99
e47) 27 (9e79) 0.86
e51) 30 (9e76) 0.81
e63) 37 (101e79) 0.74
O. Hjelmgren et al. 27examinations. Here, we established an objective software
platform that addresses a number of speciﬁc requirements.
In our experience, the appearance of contrast agent in the
plaque over time is heterogeneous and, in most cases, an
erratic process that cannot be modelled with standard
inﬂow equations. Furthermore, the technique needs to
overcome the movement artefacts generated by breathing,
the cardiac cycle and small movements of the transducer.
We found that insonation using a ﬁxed image plane crossing
the centre of the vessel at maximum plaque height gener-
ated long stable image loops suitable for interpretation
after manual correction of movement artefacts. We ana-
lysed 90-s loops and showed that by choosing a suitable
time-intensity threshold, the small changes in contrast
uptake introduced by small movements of the transducer
and plaque were averaged out. Using this technique, we
generated reproducible data in good agreement with visual
semi-quantiﬁcation. Our reproducibility data show that the
technique has an 80% power to detect 10% changes in
contrast uptake if 30 patients are included in each group.
Furthermore, it has been suggested that pseudoenhance-
ment of contrast uptake affects plaques in the far wall of
the carotid artery.22 This phenomenon can also be found in
our data but does not seem to affect interpretation of
relative changes in CQP values.
How applicable is this technique to patients with
atherosclerotic carotid disease? Its use is limited to patients
with carotid plaques of a certain size and without much
acoustic shadowing. In the current study, we found that 9%
of the hospital-based population and 7% of the healthy
population had plaques that were suitable for contrast
examination. Thus, if the technique proves valuable to
identify high-risk patients, it could be used in large patient
groups as a tool for risk stratiﬁcation.
It’s possible that CEUS could be used to determine
vulnerability within the group of plaques with low GSM.
CEUS is only suitable for plaques with little acoustic shad-
owing and therefore the average GSM in our plaques is
rather low. Previous prospective studies suggest that low
echogenicity is associated with a more vulnerable plaque
phenotype.5,6 In our group of low echogenicity plaques we
found a weak but signiﬁcant positive correlation between
contrast uptake in the plaque and echogenicity. This could
be a random ﬁnding, but it can also suggest that low
contrast uptake (and thus low vascularisation) may indicate
a higher risk of future events. This interpretation is
contradictory to previous reports showing that high
contrast uptake is found in patients with a more vulnerable
plaque phenotype.13,16,18 It is also contradictory to our
ﬁnding that contrast uptake was signiﬁcantly higher in
patients with a previous ipsilateral embolic stroke. Future
prospective studies using CEUS are required to test if CEUS
is a predictor of vulnerability.
In our population the CQP values were skewed towards
lower levels: 44% of the plaques had CQP values below
20%. This may be explained by the accumulation of plaques
with low echogenicity in our study population. Plaque with
low echogenicity most likely have a large lipid-rich necroticcore,23 which is not vascularized,1 thus limiting the possi-
bility for contrast uptake.Limitations
Correlation of CQP with visual assessment deteriorated
when the 7 training cases are deleted. This is probably due
to the limited size of the training set. Because of the small
number of plaques, it was not possible to perform multi-
variable analysis and to analyse sub-groups. Our primary
aim with this paper was to develop a standardised tech-
nique for CEUS studies. The study was not speciﬁcally
designed to test if vascularisation associates with other
indices of risk. Although our observation that contrast
uptake was signiﬁcantly higher in patients with a previous
ipsilateral embolic stroke is in agreement with previous
reports,13,16,18 the current analyses and previous reports
were done on cross-sectional data and we do not have
information on the predictive value of increased contrast
uptake. As we have previously shown, vascularisation
increases with time after the event and may thus be asso-
ciated with healing,24 which complicates interpretation of
data. These data should also be interpreted with caution
given the low number of observations and the mixed
subject group.
CEUS as a tool has several limitations that needs to be
taken into account: i. imaging is done using a hand held
transducer which introduces user dependency, ii. contrast
uptake can not be monitored in areas of the plaque shad-
owed by calciﬁcations, iii/the phenomenon of pseu-
doenhancement may affect imaging of plaques in the far
and near wall differently.Conclusion
We have presented an eligible method to measure contrast
uptake in human carotid plaques, which can be applied to
large populations. The method offers a reproducible and
objective way to identify contrast uptake in carotid plaques
and to use as an index of vascularisation. Furthermore,
contrast uptake is higher in subjects with a history of recent
ipsilateral embolic stroke. A critical evaluation of the clinical
value of contrast uptake to identify vulnerable plaques in
patients at risk of future cerebrovascular events is
important.
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